Bicara Therapeutics Common Stock Performance
| BCAX Stock | 16.80 0.11 0.65% |
Bicara Therapeutics has a performance score of 3 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.34, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Bicara Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Bicara Therapeutics is expected to be smaller as well. Bicara Therapeutics right now shows a risk of 3.81%. Please confirm Bicara Therapeutics coefficient of variation, semi variance, price action indicator, as well as the relationship between the treynor ratio and daily balance of power , to decide if Bicara Therapeutics will be following its price patterns.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Bicara Therapeutics Common are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, Bicara Therapeutics may actually be approaching a critical reversion point that can send shares even higher in March 2026. ...more
| Begin Period Cash Flow | 230.4 M | |
| Total Cashflows From Investing Activities | -9000.00 |
Bicara Therapeutics Relative Risk vs. Return Landscape
If you would invest 1,598 in Bicara Therapeutics Common on November 1, 2025 and sell it today you would earn a total of 93.00 from holding Bicara Therapeutics Common or generate 5.82% return on investment over 90 days. Bicara Therapeutics Common is currently generating 0.1633% in daily expected returns and assumes 3.8054% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Bicara, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bicara Therapeutics Target Price Odds to finish over Current Price
The tendency of Bicara Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 16.80 | 90 days | 16.80 | about 53.73 |
Based on a normal probability distribution, the odds of Bicara Therapeutics to move above the current price in 90 days from now is about 53.73 (This Bicara Therapeutics Common probability density function shows the probability of Bicara Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Bicara Therapeutics has a beta of 0.34 suggesting as returns on the market go up, Bicara Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Bicara Therapeutics Common will be expected to be much smaller as well. Additionally Bicara Therapeutics Common has an alpha of 0.1357, implying that it can generate a 0.14 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Bicara Therapeutics Price Density |
| Price |
Predictive Modules for Bicara Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Bicara Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Bicara Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Bicara Therapeutics is not an exception. The market had few large corrections towards the Bicara Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Bicara Therapeutics Common, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Bicara Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.14 | |
β | Beta against Dow Jones | 0.34 | |
σ | Overall volatility | 1.39 | |
Ir | Information ratio | 0.03 |
Bicara Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Bicara Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Bicara Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Bicara Therapeutics had very high historical volatility over the last 90 days | |
| Bicara Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (68 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bicara Therapeutics generates negative cash flow from operations | |
| Over 92.0% of the company shares are held by institutions such as insurance companies |
Bicara Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Bicara Stock often depends not only on the future outlook of the current and potential Bicara Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Bicara Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 54.4 M | |
| Cash And Short Term Investments | 489.7 M |
Bicara Therapeutics Fundamentals Growth
Bicara Stock prices reflect investors' perceptions of the future prospects and financial health of Bicara Therapeutics, and Bicara Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bicara Stock performance.
| Return On Equity | -0.27 | |||
| Return On Asset | -0.19 | |||
| Current Valuation | 620.64 M | |||
| Shares Outstanding | 54.78 M | |||
| Price To Book | 2.26 X | |||
| EBITDA | (82.33 M) | |||
| Total Debt | 738 K | |||
| Book Value Per Share | 7.38 X | |||
| Cash Flow From Operations | (74.75 M) | |||
| Earnings Per Share | 5.38 X | |||
| Total Asset | 569.2 M | |||
| Retained Earnings | (221.02 M) | |||
About Bicara Therapeutics Performance
Evaluating Bicara Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Bicara Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bicara Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about Bicara Therapeutics performance evaluation
Checking the ongoing alerts about Bicara Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bicara Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bicara Therapeutics had very high historical volatility over the last 90 days | |
| Bicara Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (68 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bicara Therapeutics generates negative cash flow from operations | |
| Over 92.0% of the company shares are held by institutions such as insurance companies |
- Analyzing Bicara Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bicara Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Bicara Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bicara Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bicara Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bicara Therapeutics' stock. These opinions can provide insight into Bicara Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Bicara Stock Analysis
When running Bicara Therapeutics' price analysis, check to measure Bicara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bicara Therapeutics is operating at the current time. Most of Bicara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Bicara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bicara Therapeutics' price. Additionally, you may evaluate how the addition of Bicara Therapeutics to your portfolios can decrease your overall portfolio volatility.